Vaxcyte reports Q3 2026 results and positive OPUS-1 data
VAX-31 met all prespecified primary endpoints in the OPUS-1 Phase 3 trial, and pro forma cash reached about $3.4 billion after $1.1 billion net proceeds.
See the latest news and media coverage for Vaxcyte. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage vaccine biotechnology company
vaxcyte.comLast updated
In short: Vaxcyte reported positive Phase 3 VAX-31 results, meeting all OPUS-1 primary endpoints.
VAX-31 met all prespecified primary endpoints in the OPUS-1 Phase 3 trial, and pro forma cash reached about $3.4 billion after $1.1 billion net proceeds.
VAX-31 met all prespecified primary endpoints in the OPUS-1 Phase 3 trial; net loss was $297.1 million versus $212.8 million a year earlier.
The company sold $575 million in convertible notes and approximately $475 million in common stock to fund operations.
The company raises up to $1.5 billion via equity and convertible debt for vaccine development and manufacturing.
Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar...
Vaxcyte’s investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all primary immunogenicity end points in the phase 3 OPUS-1 trial...
The investigational 31-valent pneumococcal conjugate vaccine (PCV) candidate VAX-31 (Vaxcyte) met all prespecified primary immunogenicity and safety end points in the pivotal phase 3 OPUS-1...
VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) Prespecified...
Track Vaxcyte and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Vaxcyte and other trending companies.